VERITAC-2 trial shows vepdegestrant improves progression-free survival in ESR1-mutant breast cancer, marking a clinical milestone for PROTAC therapy. The trial did not reach statistical ...

NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus ...

Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the ...

Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – ...

Q1 2025 Management View CEO John Houston highlighted the company's progress in advancing Vepdegestrant (VEPDEG), noting it recently achieved positive pivotal data from the VERITAC-2 study in ESR1 ...

Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared to the older degrader fulvestrant in a subset of HR ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings - - Presented first-in-human data for the Company's first neuroscience program with ARV-102 ...